Details for Patent: 7,994,364
✉ Email this page to a colleague
Which drugs does patent 7,994,364 protect, and when does it expire?
Patent 7,994,364 protects NUCYNTA and NUCYNTA ER and is included in three NDAs.
This patent has forty-five patent family members in twenty-six countries.
Summary for Patent: 7,994,364
Title: | Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Abstract: | A hitherto unknown crystalline form of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence. |
Inventor(s): | Fischer; Andreas (Huertgenwald, DE), Buschmann; Helmut (Esplugues de Llobregat, ES), Gruss; Michael (Aachen, DE), Lischke; Dagmar (Eschweiler, DE) |
Assignee: | Gruenenthal GmbH (Aachen, DE) |
Application Number: | 12/634,777 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,994,364 |
Patent Claim Types: see list of patent claims | Compound; Process; Composition; Use; |
Drugs Protected by US Patent 7,994,364
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Collegium Pharm Inc | NUCYNTA | tapentadol hydrochloride | SOLUTION;ORAL | 203794-001 | Oct 15, 2012 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN | ⤷ Try a Trial | ||
Collegium Pharm Inc | NUCYNTA ER | tapentadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200533-001 | Aug 25, 2011 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY | ⤷ Try a Trial | ||
Collegium Pharm Inc | NUCYNTA ER | tapentadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200533-001 | Aug 25, 2011 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | RELIEF OF MODERATE TO SEVERE CHRONIC PAIN | ⤷ Try a Trial | ||
Collegium Pharm Inc | NUCYNTA ER | tapentadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200533-002 | Aug 25, 2011 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | RELIEF OF MODERATE TO SEVERE CHRONIC PAIN | ⤷ Try a Trial | ||
Collegium Pharm Inc | NUCYNTA ER | tapentadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200533-002 | Aug 25, 2011 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY | ⤷ Try a Trial | ||
Collegium Pharm Inc | NUCYNTA ER | tapentadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200533-003 | Aug 25, 2011 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,994,364
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
04015091 | Jun 28, 2004 |
International Family Members for US Patent 7,994,364
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 049949 | ⤷ Try a Trial | |||
Argentina | 116052 | ⤷ Try a Trial | |||
Austria | E368639 | ⤷ Try a Trial | |||
Austria | E496021 | ⤷ Try a Trial | |||
Australia | 2005256512 | ⤷ Try a Trial | |||
Brazil | 122018014454 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |